X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Overcoming challenges in effervescent dosage manufacturing

Content Team by Content Team
19th October 2021
in Drug Development, News
Overcoming challenges in effervescent dosage manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

To improve the taste and stability of effervescent tablets and powders, BENEO presents galenIQ™ 721. This filler-binder enables pharmaceutical and nutraceutical manufacturers to target consumers that have difficulty swallowing standard tablets. As a non-hygroscopic, water-soluble and directly compressible excipient, galenIQ™ 721 also provides high content uniformity and production efficiency for effervescent applications.

Effervescent dosage forms offer distinct advantages compared with traditional tablets. For instance, many patients have problems swallowing tablets. Effervescent powders and tablets offer a more convenient way to deliver medicines or dietary supplements. They dissolve upon contact with water to release carbon dioxide and create a drink. In addition, they can be used to formulate pharmaceuticals that are difficult to digest, that cause stomach or esophageal irritation or that rely on a rapid onset of action, such as analgesics.

However, manufacturing effervescent dosage forms is often challenging. To produce highly stable tablets, a non-hygroscopic, direct compression filler-binder such as galenIQ™ 721 is needed. It ensures high content uniformity and facilitates production. BENEO’s excipient has a sugar-like taste profile, a pleasant mouthfeel and can enhance the palatability of effervescent formulations. Furthermore it is non-cariogenic and therefore is both sweet and tooth-friendly.

Dr Maj-Britt Cepok, Head of Business Development, Pharma, BENEO, comments: “Fizzy tablets are ideally suited to administer a wide range of light-, oxygen- and other sensitive active ingredients and those that require a large dose. In addition, effervescent preparations are more appealing to consumers than traditional dosage forms. galenIQ™ 721 helps manufacturers to tap into this market and enhance their development programs.”

About galenIQ™
BENEO is part of the Südzucker Group and a member of the International Pharmaceutical Excipients Council (IPEC). The company produces galenIQ™ (Isomalt Ph. Eur., BP, USP-NF, JP), a multifunctional range of water-soluble filler-binders according to cGMP conditions for pharmaceutical excipients. galenIQ™ is available in a wide variety of median particle sizes, morphologies and solubilities and
therefore is readily used in solid and liquid dosage forms such as tablets, sachets, effervescents, lozenges and syrups. It is physically and chemically stable, non-hygroscopic and enhances the palatability of the final form.

Previous Post

Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment

Next Post

Ophthalmic Company Implandata Awarded as Top 12 Healthcare Innovator at Medica, World Forum for Medicine

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
Ophthalmic Company Implandata Awarded as Top 12 Healthcare Innovator at Medica, World Forum for Medicine

Ophthalmic Company Implandata Awarded as Top 12 Healthcare Innovator at Medica, World Forum for Medicine

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In